Atomo Diagnostics Cheers Federal HIV Funding Boost
Company Announcements

Atomo Diagnostics Cheers Federal HIV Funding Boost

Atomo Diagnostics Ltd. (AU:AT1) has released an update.

Atomo Diagnostics Ltd. has welcomed the Australian Federal Government’s budget allocation of $43.9 million towards expanding HIV Self-Testing, aiming to eliminate HIV transmission by 2030. The company, which supplies the only ARTG-listed HIV Self-Test, expects a significant portion of the funds to support the procurement of their tests as part of the national HIV self-test mail-out program and vending machine pilot expansion. This funding follows the recognition of the importance of self-testing in meeting national HIV targets, and Atomo is committed to ensuring widespread access to these tests.

For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App